Fortis Healthcare Q1FY27 Consolidated Revenue at ₹2,545 Crore, Up 17.5%
Fortis Healthcare reported Q1FY27 consolidated revenue of ₹2,545 crore, up 17.5% YoY. Operating EBITDA increased by 15.8% to ₹568 crore. Hospital business revenue grew 19% to ₹2,187 crore, and diagnostics business revenue rose 10.2% to ₹407 crore. Net debt was ₹2,233 crore.
The announcement of quarterly financial results, especially with significant year-on-year growth in revenue and EBITDA, is a material event for investors and has a high impact on the company's stock.
The company has reported strong year-on-year growth in revenue and operating EBITDA for the quarter, indicating positive business performance. Key business segments like hospitals and diagnostics have also shown significant growth.
Fortis Healthcare Limited has announced its financial results for the first quarter of fiscal year 2027 (Q1FY27), reporting a consolidated revenue of ₹2,545 crore, a 17.5% increase compared to ₹2,167 crore in Q1FY26. The consolidated Operating EBITDA stood at ₹568 crore, up 15.8% from ₹491 crore in the same period last year. Profit Before Tax (PBT) before exceptional items was ₹354 crore, an increase of 4.6% from ₹338 crore in Q1FY26. The consolidated Profit After Tax (PAT) was ₹263 crore, a marginal increase of 3.6% from ₹254 crore in Q1FY26. The company's net debt stood at ₹2,233 crore as of June 30, 2026, with a Net Debt to EBITDA ratio of 1.01x.
The hospital business revenue grew by 19.0% to ₹2,187 crore, while the hospital business operating EBITDA was ₹471 crore, up 15.9%. The diagnostics business reported gross revenues of ₹407 crore, a 10.2% increase YoY, with an operating EBITDA margin of 23.9%.
The company also highlighted clinical excellence initiatives, including the inauguration of advanced DaVinci Xi Robotic Surgical Systems at two of its facilities and the launch of a Centre of Excellence for Myeloma & Lymphoma. The investor presentation was made available on August 06, 2026.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.